The companies will employ Jerini's Peptides-to-Drugs discovery platform, including SPOT, pepSPOT, and pepMED, along with other technologies to generate peptidomemetic and small molecule drug candidates and validate their utility for the treatment of eye diseases.
Jerini will receive up-front and license fees, as well as personnel funding, milestone payments, and worldwide royalties on commercial sales of products resulting from the collaboration.
Financial terms of the agreement were not disclosed.